Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic
hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of …

Background Pilot clinical trials have shown the safety of intra-arterial bone marrow
mononuclear cells (BMMNCs) in stroke. However, the efficacy of different doses of intra-arterial …

Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are
currently being evaluated as therapeutic options in the treatment of chronic graft versus host …

Previous studies have shown the potential of microRNAs (miRNA) in the pathological
process of stroke and functional recovery. Bone marrow mononuclear cell (BM-MNC) …

Methods A descriptive, retrospective, multi-centre study of adult and paediatric patients (< 14
years) treated with ruxolitinib for steroid-refractory acute or chronic GvHD from 16 Spanish …

Background: Obe-cel (AUTO1) is an autologous CD19CAR with a fast off-rate CD19 binding
domain designed to reduce CAR-T immunotoxicity and improve persistence. Its clinical …

2. METHODS Between October 2015 to July 2017, 79 patients received ruxolitinib under a
compassionate use program and were evaluated in this retrospective study using data …

Introduction Chronic Graft versus Host Disease (cGvHD) remains a major complication of
hematopoietic stem cells transplantation (HSCT) causing significant morbidity and mortality. …

The morphologic hallmark of Chédiak-Higashi syndrome, a rare autosomal recessive disorder
characterized by increased fusion of cytoplasmic granules and cellular dysfunction, is the …

Methods). Demographics and clinical characteristics of the patients are detailed in the Online
Supplementary Table S1. Fifty-eight (61.1%) patients showed HAdV viremia episodes, all …